BioSpace News Archive

Today, GetMyDNA announces the launch of their consumer-initiated Pharmacogenetics at-home test kit. Pharmacogenetics (PGx) testing measures the body’s response to specific drugs.

Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate updates.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now under evaluation with the European Medicines Agency (EMA).

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 550,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today.

Vitro Biopharma, Inc. announced the signing of a contract with European Wellness Biomedical Group headquartered in Kuala Lumpur, Malaysia and it’s start-up subsidiary BioPep being registered in Delaware, USA to develop FDA-approval of biological products derived from existing mitochondrial peptide extracts

Increase in prevalence of infectious diseases, bloodstream infections, and sepsis drives the growth of the global blood culture test market.

Flood popular for illness analysis, ease gave in counsel, and digitalization in the clinical business are factors that drive the development of the worldwide pathology market

Rising incidences of chronic diseases, extensive demand for early diagnosis and treatment of various diseases and disorders coupled with the need to enhance the quality of healthcare will invite substantial growth prospects for the multiparameter patient monitoring systems market during the forecast period of 2020-2030.